135 related articles for article (PubMed ID: 9892183)
1. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity.
Labourier E; Riou JF; Prudhomme M; Carrasco C; Bailly C; Tazi J
Cancer Res; 1999 Jan; 59(1):52-5. PubMed ID: 9892183
[TBL] [Abstract][Full Text] [Related]
2. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
Pilch B; Allemand E; Facompré M; Bailly C; Riou JF; Soret J; Tazi J
Cancer Res; 2001 Sep; 61(18):6876-84. PubMed ID: 11559564
[TBL] [Abstract][Full Text] [Related]
3. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
Moreau P; Anizon F; Sancelme M; Prudhomme M; Bailly C; Carrasco C; Ollier M; Sevère D; Riou JF; Fabbro D; Meyer T; Aubertin AM
J Med Chem; 1998 May; 41(10):1631-40. PubMed ID: 9572888
[TBL] [Abstract][Full Text] [Related]
4. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
5. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
[TBL] [Abstract][Full Text] [Related]
6. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
7. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
8. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
Qu X; Chaires JB; Ohkubo M; Yoshinari T; Nishimura S; Bailly C
Anticancer Drug Des; 1999 Oct; 14(5):433-42. PubMed ID: 10766298
[TBL] [Abstract][Full Text] [Related]
9. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110.
Yoshinari T; Yamada A; Uemura D; Nomura K; Arakawa H; Kojiri K; Yoshida E; Suda H; Okura A
Cancer Res; 1993 Feb; 53(3):490-4. PubMed ID: 8381047
[TBL] [Abstract][Full Text] [Related]
10. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
11. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
Bailly C; Dassonneville L; Colson P; Houssier C; Fukasawa K; Nishimura S; Yoshinari T
Cancer Res; 1999 Jun; 59(12):2853-60. PubMed ID: 10383146
[TBL] [Abstract][Full Text] [Related]
12. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
13. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
14. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent.
Moreau P; Anizon F; Sancelme M; Prudhomme M; Bailly C; Sevère D; Riou JF; Fabbro D; Meyer T; Aubertin AM
J Med Chem; 1999 Feb; 42(4):584-92. PubMed ID: 10052965
[TBL] [Abstract][Full Text] [Related]
15. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
[TBL] [Abstract][Full Text] [Related]
16. An insight into the mechanism of inhibition of unusual bi-subunit topoisomerase I from Leishmania donovani by 3,3'-di-indolylmethane, a novel DNA topoisomerase I poison with a strong binding affinity to the enzyme.
Roy A; Das BB; Ganguly A; Bose Dasgupta S; Khalkho NV; Pal C; Dey S; Giri VS; Jaisankar P; Dey S; Majumder HK
Biochem J; 2008 Jan; 409(2):611-22. PubMed ID: 17922678
[TBL] [Abstract][Full Text] [Related]
17. Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.
Das BB; Sen N; Roy A; Dasgupta SB; Ganguly A; Mohanta BC; Dinda B; Majumder HK
Nucleic Acids Res; 2006; 34(4):1121-32. PubMed ID: 16488884
[TBL] [Abstract][Full Text] [Related]
18. Indolocarbazole glycosides in inactive conformations.
Facompré M; Carrasco C; Vezin H; Chisholm JD; Yoburn JC; Van Vranken DL; Bailly C
Chembiochem; 2003 May; 4(5):386-95. PubMed ID: 12740810
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human DNA topoisomerase IB by a cyclometalated gold III compound: analysis on the different steps of the enzyme catalytic cycle.
Castelli S; Vassallo O; Katkar P; Che CM; Sun RW; Desideri A
Arch Biochem Biophys; 2011 Dec; 516(2):108-12. PubMed ID: 22033340
[TBL] [Abstract][Full Text] [Related]
20. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S
Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
